About Us

BELLUS Health is a clinical stage biotechnology company focused on developing a P2X3 antagonist to address chronic cough and other hypersensitization disorders. The Company’s lead candidate, BLU-5937, is a highly selective P2X3 antagonist currently being developed for the treatment of chronic cough. The Company plans to initiate Phase 3 registration trials in the second half of 2022.  BELLUS Health is also exploring how inhibition of P2X3 receptors can help treat other afferent hypersensitization-related disorders.

We invite you to visit our investors’ relations page, including our Annual Information Form, to obtain more information about BELLUS Health.

View More

P2X3 Receptors and Chronic Cough

P2X3 receptors are ion channels expressed on sensory nerves throughout the body and play an important role in the sensitization to various stimuli.1 P2X3-induced hypersensitization in the airways may result in an exaggerated urge to cough, refractory to the treatment of otherwise identifiable causes.2 Bellus Heath is investigating the P2X3 antagonist, BLU-5937, as a potential treatment for refractory chronic cough.